Personalis, Inc.

Personalis, Inc. has entered into a definitive Agreement and Plan of Merger with Tempus AI, Inc. on July 20, 2026. Under the agreement, Personalis will become a wholly-owned subsidiary of Tempus AI through a two-step merger process. Personalis stockholders will receive shares of Tempus AI Class A Common Stock, with Tempus AI having the option to elect cash for up to 50% of the aggregate outstanding shares at $16.25 per share. The boards of both companies have approved the transaction, and a major stockholder, Merck Sharp & Dohme LLC, has agreed to vote in favor of the merger.

Personalis, Inc. announced it has entered into a definitive agreement to be acquired by Tempus AI, Inc. for $16.25 per share, valuing the company at $1.5 billion. This represents a 6% premium to Personalis' closing price and a 28% premium to its unaffected 30-day VWAP. The acquisition, expected to close in late 2026 or early 2027, will integrate Personalis' molecular residual disease (MRD) technology into Tempus' precision oncology platform. Personalis also reported preliminary Q2 2026 revenue of $22.4 million, with clinical test volumes increasing 33% to 10,384.

Personalis, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program has expanded Medicare coverage for its ultrasensitive NeXT Personal® test. This expansion now includes immunotherapy monitoring for patients diagnosed with late-stage solid tumors. The new coverage became effective on May 12, 2026, significantly broadening the test's utility and market access.

Personalis, Inc. reported a significant widening of its net loss and a decrease in revenue for the first quarter of 2026 compared to the same period in 2025. Revenue fell to $15.5 million from $20.6 million, while the net loss increased to $30.0 million from $15.8 million. The company continues to invest heavily in research and development and sales and marketing efforts, expecting to incur additional losses for the foreseeable future.

Personalis, Inc. reported its first quarter 2026 financial results, with total revenue decreasing to $15.5 million from $20.6 million year-over-year. Despite the overall revenue decline and widened net loss, clinical test volume surged 258% to 7,815 tests, driving clinical revenue to $1.4 million. The company secured Medicare coverage for lung cancer surveillance, marking its second major coverage decision in six months, and reaffirmed its full-year 2026 financial guidance, projecting a five-fold growth in clinical revenue.